ADVENTRX Pharmaceuticals Inc (Anx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Keith Feral	11/7/2006 11:35:17 AM
	Read Replies (1) of 418

Adventrx came out with an interesting slide show for the conferences. They are expecting Cofactor to generate over $400 million in US revenues for colorectal cancer. That doesn't include global opportunities in Asia and Europe. Also, the money from the secondary will be used to fund new clinical trials for Breast cancer. That would essentially double the market for cofactor in cancer treatments. When you consider the fact that drugs like Avastin have been tested for dozens of types of cancer, the market for cofactor is just getting started.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next